Does Blue Cross Blue Shield of Texas Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Forteo is the brand name for teriparatide, a recombinant fragment of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing resorption. The FDA approved teriparatide in 2002 for postmenopausal women with osteoporosis at high fracture risk, and a separate indication covers men and glucocorticoid-induced osteoporosis as well. Because it is an injectable specialty biologic, it lands on Specialty Tier formulary positions across nearly every commercial plan, including Blue Cross Blue Shield of Texas products sold through the employer, marketplace, and Medicare Advantage channels.

The complexity around coverage comes from two directions. First, the drug's list price is high. Second, clinical guidelines from the American Association of Clinical Endocrinology (AACE) and the Endocrine Society reserve anabolic agents like teriparatide for patients at very high or imminent fracture risk, not as first-line therapy for every osteoporosis diagnosis. Insurers follow those same clinical thresholds when writing medical necessity criteria. Understanding the pharmacology helps here. The key Fracture Prevention Trial (N=1,637) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fractures by 53% versus placebo over a median 21-month follow-up, establishing why the drug earns its specialty status. That trial is indexed at PubMed.

BCBS Texas administers plans under several legal entities, including HCSC (Health Care Service Corporation). The specific formulary your plan uses depends on whether you have a PPO, HMO, or marketplace plan. Checking the Summary of Benefits and Coverage document and the live formulary search tool on the BCBS Texas member portal is the fastest way to confirm your plan's exact tier and cost-share for teriparatide before your provider submits a prior authorization.

How Prior Authorization Works for Forteo at BCBS Texas

Prior authorization (PA) is mandatory. BCBS Texas will not process a teriparatide claim without it.

Your prescribing physician, typically an endocrinologist or rheumatologist, submits a PA request that documents your bone mineral density (BMD) results, fracture history, prior drug trials, and the clinical rationale for choosing an anabolic agent over continued antiresorptive therapy. The Endocrine Society's 2019 clinical practice guideline states: "Anabolic therapy should be considered for patients with very high fracture risk, defined as T-score below -3.0, multiple vertebral fractures, or fracture while on antiresorptive therapy." Full guideline text is available at the Endocrine Society.

BCBS Texas typically requires all of the following before approving teriparatide:

A DEXA scan T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, or documentation of a low-trauma (fragility) fracture. Patients must also have tried and failed, or have a documented contraindication to, at least one oral bisphosphonate such as alendronate or risedronate. Failure means either inadequate BMD response (continued bone loss greater than the least significant change) or an intolerable gastrointestinal adverse event confirmed in the medical record. Bisphosphonate efficacy benchmarks are reviewed here. The FRAX score, a WHO-validated fracture probability tool, may also be submitted to strengthen the PA. The FRAX methodology is published at NCBI.

Once submitted, BCBS Texas is legally required under Texas state insurance code to render a standard PA decision within 15 calendar days of receiving all necessary clinical information. For urgent situations involving imminent fracture risk, the turnaround is 72 hours. If your PA is denied, you have the right to request a peer-to-peer review between your physician and the BCBS TX medical director, which reverses many initial denials in the osteoporosis specialty category.

What BCBS Texas Specifically Looks for in the Medical Record

Documentation quality determines approval speed. The PA reviewer is checking for specific data points, not narrative summaries.

The DEXA report itself must state the T-score numerically and include the scan date. Reports older than 24 months carry less weight unless a more recent scan shows continued decline. DEXA scanning protocols and precision standards are outlined by the International Society for Clinical Densitometry. The fracture history section should include imaging reports, preferably a vertebral fracture assessment (VFA) or dedicated spine X-ray, not just a clinical note saying "history of compression fracture."

For the step-therapy component, the medical record must show a prescription fill history for a bisphosphonate lasting at least 12 months, or a clear documented reason why bisphosphonate therapy could not be used. Acceptable contraindications include esophageal motility disorders, inability to remain upright for 30 minutes after dosing, estimated GFR below 35 mL/min/1.73 m², and documented severe gastrointestinal intolerance confirmed on two separate occasions. Atypical femoral fracture on prior bisphosphonate therapy is another accepted contraindication. Bisphosphonate contraindications and GFR thresholds are reviewed here.

A FRAX 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3%, supports the PA under the National Osteoporosis Foundation (NOF) treatment threshold and the AACE 2020 guidelines. The AACE 2020 osteoporosis guideline is indexed here. Submitting the FRAX printout alongside the PA form removes ambiguity and reduces back-and-forth requests for additional information.

Cost-Share, Copays, and What You Can Actually Expect to Pay

Specialty tier cost-share for teriparatide on BCBS Texas plans commonly falls between 25% and 40% coinsurance, which translates to $800 to $1,400 per month on a drug with a list price near $3,200 for a 28-day pen. Those numbers are before any deductible is met.

Three programs can reduce that burden substantially. First, Eli Lilly's Forteo Savings Card program historically caps eligible commercially insured patients at $25 to $100 per fill, though terms change annually and income limits apply. Second, Eli Lilly's patient-assistance program (LillyCaresFoundation.org) provides Forteo at no cost to uninsured or underinsured patients who meet federal poverty level criteria. Third, the 340B Drug Pricing Program allows qualifying hospital-based outpatient clinics and federally qualified health centers to dispense teriparatide at sharply reduced cost to eligible patients. The 340B program statute is available at HRSA.

Once your plan deductible is satisfied, your cost-share applies only to the remaining balance. For patients with a $3,000 deductible who begin teriparatide in January, the first month is expensive. Months two through twelve may cost considerably less depending on your out-of-pocket maximum. Checking your Explanation of Benefits documents each month is the practical way to track accumulation.

Biosimilar Teriparatide: Bonsity as a Lower-Cost Alternative

Bonsity (teriparatide-tbwh), manufactured by Alvogen, received FDA approval in June 2021 as a biosimilar to Forteo. The FDA biosimilar approval letter is on FDA.gov. Many BCBS Texas formularies now place Bonsity on a lower specialty tier or assign it a lower coinsurance percentage than brand Forteo, making it a meaningful option for cost reduction.

Biosimilars are not generics, but the FDA's approval standard for biosimilars requires no clinically meaningful differences in safety, purity, or potency compared to the reference product. The FDA biosimilar guidance explains this standard here. In practice, Bonsity delivers the same 20 mcg/day teriparatide dose using the same subcutaneous injection mechanism. If your prescribing physician writes "brand medically necessary" on the Forteo prescription, BCBS TX may still allow the substitution depending on your plan's non-interference policy. Asking your endocrinologist to write the prescription as "teriparatide" rather than specifying Forteo by brand can allow the specialty pharmacy to dispense whichever formulation sits on the lower tier for your specific plan.

The 24-Month Lifetime Limit: Planning Your Treatment Window

The FDA restricts cumulative teriparatide use to 24 months over a patient's lifetime, and BCBS Texas mirrors that restriction in its coverage criteria. The FDA labeling for Forteo documents this limit.

This means sequencing matters. AACE and the Endocrine Society both recommend following anabolic therapy with antiresorptive consolidation. A 2019 study in JAMA (N=94, 12-month extension data from ACTIVE trial) showed that women who transitioned from abaloparatide to alendronate maintained BMD gains, and a parallel principle applies after teriparatide: transitioning to a bisphosphonate or denosumab preserves the bone mass built during anabolic therapy. That JAMA data is available here. Without antiresorptive follow-up, BMD gains from teriparatide are largely lost within 12 to 18 months. Your physician should discuss the sequential treatment plan before starting teriparatide, because BCBS TX may require documentation that a follow-on antiresorptive is planned as part of the PA approval process.

Patients who have already used teriparatide for 24 months are not eligible for a second course under FDA labeling, and BCBS TX will not authorize a second 24-month course. Abaloparatide (Tymlos) or romosozumab (Evenity) may be options for those patients depending on their clinical situation and plan formulary, though those drugs carry their own PA requirements. Abaloparatide trial data from the ACTIVE trial is indexed here.

What Happens If BCBS Texas Denies the Prior Authorization

Denial is not the end. A structured appeal process exists, and success rates improve substantially when the appeal is physician-led.

The first step after denial is the peer-to-peer review. Your endocrinologist calls the BCBS TX medical director and presents the clinical case verbally. This is not a formal appeal, and it carries no cost to you. Peer-to-peer reviews resolve a meaningful percentage of specialty drug denials without requiring a formal written appeal.

If the peer-to-peer fails, you file a Level 1 (internal) appeal within 180 days of the denial notice. The appeal letter should cite the AACE 2020 guideline recommendation that anabolic therapy is appropriate for patients at very high fracture risk, include a copy of the DEXA report with T-scores, attach any fracture imaging, and reference the Fracture Prevention Trial data showing 65% vertebral fracture reduction. The Fracture Prevention Trial is at PubMed here. BCBS TX must respond to a Level 1 appeal within 30 days for non-urgent requests.

A Level 2 (external) appeal goes to an independent review organization (IRO) designated by the Texas Department of Insurance. External appeals are binding on the insurer. The Texas Department of Insurance's consumer protection division can assist patients who believe the denial is unjustified. Texas Department of Insurance consumer resources are at TDI.Texas.gov.

During the appeal period, ask your prescribing physician about free samples or bridge-supply programs from Eli Lilly, which can sometimes provide a month or two of medication while the appeal is pending.

Glucocorticoid-Induced Osteoporosis: A Separate Coverage Pathway

Patients on long-term glucocorticoid therapy, defined as prednisone 5 mg/day or more for three or more consecutive months, qualify for a different coverage pathway at BCBS TX. The ACR 2022 glucocorticoid-induced osteoporosis guideline is here. The American College of Rheumatology's 2022 guideline recommends teriparatide as the preferred anabolic agent in very-high-risk glucocorticoid-induced osteoporosis, even when T-scores are above the standard -2.5 threshold.

This matters clinically because glucocorticoids suppress osteoblast activity and impair bone formation through a different mechanism than postmenopausal estrogen withdrawal. Fracture risk rises faster relative to T-score in glucocorticoid users than in postmenopausal women without steroid exposure. BCBS Texas plans generally accept the ACR guideline criteria for PA approval in this population, meaning a patient on high-dose prednisone for rheumatoid arthritis or inflammatory bowel disease may qualify for teriparatide even with a T-score between -1.5 and -2.5, provided the ACR risk-stratification criteria are met and documented. Glucocorticoid-induced bone loss mechanisms are reviewed at NCBI.

The step-therapy requirement may still apply, but the bisphosphonate trial period is sometimes shortened or waived when there is a documented contraindication in glucocorticoid-treated patients, because this population is at higher gastrointestinal risk from both the steroids and oral bisphosphonates simultaneously. Document that risk explicitly in the PA submission.

Male Osteoporosis Coverage: What BCBS TX Does Differently

Teriparatide is FDA-approved for men with primary or hypogonadal osteoporosis, and BCBS Texas covers it in men under the same general PA framework used for postmenopausal women. However, the step-therapy requirement is applied with some nuance. Alendronate (Fosamax) is FDA-approved for male osteoporosis and is the expected first-line agent. Risedronate and zoledronic acid are also approved options. FDA-approved indications for alendronate in men are on FDA.gov.

Men who fail bisphosphonate therapy, who present with very high fracture risk at diagnosis, or who have hypogonadism-driven bone loss with T-scores below -2.5 have a clear clinical case for teriparatide. The PA documentation for male patients should include testosterone levels if hypogonadism is suspected, because untreated hypogonadism is both a contraindication to initiating teriparatide without hormonal optimization and an independent fracture risk factor. Male osteoporosis management is reviewed in this NEJM article. Treating the underlying hypogonadism with testosterone replacement therapy before or alongside teriparatide may also be a separate coverage discussion with BCBS TX.

Navigating the Specialty Pharmacy Requirement

BCBS Texas requires teriparatide to be dispensed through a contracted specialty pharmacy. Walgreens Specialty Pharmacy, CVS Specialty, and Accredo are among the contracted specialty pharmacies most commonly associated with HCSC-administered plans, though the list changes annually.

Dispensing teriparatide through a non-contracted pharmacy will result in a rejected claim or out-of-network cost-share, which can be substantially higher. Your prescriber's office should confirm the contracted specialty pharmacy with BCBS TX at the time the PA is submitted, then send the prescription directly to that pharmacy. The specialty pharmacy's clinical team will typically call you to complete a benefits investigation, confirm the PA approval, and schedule shipment. Teriparatide pens require refrigeration and are shipped in temperature-controlled packaging. Cold-chain storage requirements for biologics are summarized by FDA guidance here.

First fills sometimes take seven to ten business days after PA approval because of the benefits-investigation step. Requesting expedited processing at the specialty pharmacy when fracture risk is acute or the patient is post-hospitalization for a fracture is appropriate and may shorten that window.